Amgen to discuss application for LUMAKRAS® (sotorasib) for the treatment of KRAS G12C
 

Amgen today announced the*U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee*(ODAC) will review data supporting the supplemental New Drug Application (sNDA) for the full approval of LUMAKRAS®*(sotorasib) for adults with previously treated locally advanced or metastatic*KRAS*G12C-mutated non-small cell lung cancer (NSCLC) at a meeting on*Oct. 5, 2023.

More...